What is Biofourmis?
Headquartered in Boston with a robust international footprint, Biofourmis leverages advanced artificial intelligence to bridge the gap between hospital-level care and the home environment. By synthesizing data from over 120 real-time biomarkers, the company enables proactive clinical interventions that reduce readmission rates and optimize patient outcomes. Following its strategic merger with CopilotIQ, the firm now offers a comprehensive, end-to-end platform that manages the entire patient journey, from pre-surgical optimization to acute and post-acute care management, positioning it as a critical infrastructure provider for modern health systems and life science organizations.
How much funding has Biofourmis raised?
Biofourmis has raised a total of $561.1M across 7 funding rounds:
Private Equity
$1M
Series A
$5M
Series B
$35M
Debt
$150K
Series C
$100M
Series D
$320M
Series C
$100M
Private Equity (2016): $1M with participation from Eden Strategy and SpesNet
Series A (2017): $5M led by NSI Ventures, Aviva, and The Northstar Group
Series B (2019): $35M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Series C (2020): $100M backed by EDBI, MassMutual Ventures, Steamboat Ventures, Softbank Capital, and Openspace Ventures
Series D (2022): $320M with participation from Trevor Fetter, CVS Health, and General Atlantic
Series C (2025): $100M led by Edbi, Massachusetts Mutual Life Insurance, Sequoia Capital, SoftBank Corp, and Openspace Ventures
Key Investors in Biofourmis
Sequoia Capital
A premier venture capital firm with a storied history of backing global market leaders, focusing on long-term partnerships with entrepreneurs across the venture and growth stages.
General Atlantic
A global growth equity firm that provides strategic capital and operational support to high-growth companies in the healthcare, life sciences, and technology sectors.
SoftBank Corp
A major Japanese telecommunications and technology conglomerate that invests in next-generation social infrastructure and AI-enabled digital ecosystems.
What's next for Biofourmis?
With this latest round of financing, Biofourmis is poised to accelerate its market expansion and deepen its technological capabilities in AI-enabled infrastructure. The company's focus remains on scaling its virtual care delivery models and enhancing its predictive analytics engine to meet the growing demand for decentralized clinical trials. By integrating its platform deeper into the global healthcare ecosystem, Biofourmis aims to drive digital transformation, ensuring that high-acuity care becomes more accessible, efficient, and data-informed for patients and providers alike.
See full Biofourmis company page
